Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32171038,steady-state concentration (CS-S,"Mean steady-state concentration (CS-S , SD) reached 209 (22) ng/ml.","GABAergic modulation of secondary hyperalgesia: A randomized controlled 4-way crossover trial with the α2-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32171038/),[ng] / [ml],209,6185,DB01068,Clonazepam
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,43.3,15735,DB01068,Clonazepam
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,14.1,15736,DB01068,Clonazepam
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,28.9,15737,DB01068,Clonazepam
,3596609,elimination half-lives,CBZ and CBZ-E elimination half-lives were 26 and 16.5 h respectively.,"Carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics in an overdose patient. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596609/),h,26,32865,DB01068,Clonazepam
,3596609,elimination half-lives,CBZ and CBZ-E elimination half-lives were 26 and 16.5 h respectively.,"Carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics in an overdose patient. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3596609/),h,16.5,32866,DB01068,Clonazepam
,33387837,flow rate,"Chromatographic analysis was performed on the C18 column (Blue Orchid, 1.8 μm, 50 × 2 mm) using 0.1 % formic acid in water (pH 2.6) and acetonitrile (60:40; v/v) as mobile phase at a flow rate of 0.5 mL/min.",Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33387837/),[ml] / [min],0.5,48196,DB01068,Clonazepam
,33387837,limit of quantification (LOQ),"The limit of quantification (LOQ) was 20 and 5 ng/mL for SOF and LED, respectively.",Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33387837/),[ng] / [ml],20,48197,DB01068,Clonazepam
,33387837,limit of quantification (LOQ),"The limit of quantification (LOQ) was 20 and 5 ng/mL for SOF and LED, respectively.",Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33387837/),[ng] / [ml],5,48198,DB01068,Clonazepam
,33387837,total analysis time,The results of inter-day and intra-day precision showed good reproducibility and the total analysis time was 1.2 min.,Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33387837/),min,1.2,48199,DB01068,Clonazepam
,1233263,volume of distribution ((Vd)beta),The volume of distribution ((Vd)beta) ranged between 1.5 and 4.4 l/kg and the plasma half-life (t1/2) between 19 and 60 hours.,Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233263/),[l] / [kg],1.5 and 4.4,54340,DB01068,Clonazepam
,1233263,plasma half-life (t1/2),The volume of distribution ((Vd)beta) ranged between 1.5 and 4.4 l/kg and the plasma half-life (t1/2) between 19 and 60 hours.,Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233263/),h,19 and 60,54341,DB01068,Clonazepam
,2743490,bioavailability,"The bioavailability of CZP from the gel ointment was 47.2 +/- 3.1%, which was significantly larger than that (3.3 +/- 0.5%) after the ointment without Azone or that (12.5 +/- 3.6%) after oral administration.",Percutaneous absorption of clonazepam in rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743490/),%,47.2,54609,DB01068,Clonazepam
,2743490,bioavailability,"The bioavailability of CZP from the gel ointment was 47.2 +/- 3.1%, which was significantly larger than that (3.3 +/- 0.5%) after the ointment without Azone or that (12.5 +/- 3.6%) after oral administration.",Percutaneous absorption of clonazepam in rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743490/),%,3.3,54610,DB01068,Clonazepam
,2743490,bioavailability,"The bioavailability of CZP from the gel ointment was 47.2 +/- 3.1%, which was significantly larger than that (3.3 +/- 0.5%) after the ointment without Azone or that (12.5 +/- 3.6%) after oral administration.",Percutaneous absorption of clonazepam in rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743490/),%,12.5,54611,DB01068,Clonazepam
,8848810,clearance (CL/F),"With controlled dosing and postdose sample collection times, large variations were observed in calculated CZP nitroreduction rates [clearance (CL/F) ranged from 7 to 64 ml/h/kg] as well as 7ACZP acetylation rates (CL/F from 10 to 85 ml/h/kg).",Clonazepam disposition in pediatric patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848810/),[ml] / [h·kg],7 to 64,57268,DB01068,Clonazepam
,8848810,CL/F,"With controlled dosing and postdose sample collection times, large variations were observed in calculated CZP nitroreduction rates [clearance (CL/F) ranged from 7 to 64 ml/h/kg] as well as 7ACZP acetylation rates (CL/F from 10 to 85 ml/h/kg).",Clonazepam disposition in pediatric patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848810/),[ml] / [h·kg],10 to 85,57269,DB01068,Clonazepam
,6732363,terminal elimination half-life (t0.5 beta or,"After i.v. administration of 0.2 mg/kg clonazepam to dogs, plasma concentrations followed partly a biexponential and partly a monoexponential decline, the terminal elimination half-life (t0.5 beta or t0.5) being 1.4 +/- 0.3 hr.",Pharmacokinetics of clonazepam in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6732363/),h,1.4,59219,DB01068,Clonazepam
,6732363,t0.5),"After i.v. administration of 0.2 mg/kg clonazepam to dogs, plasma concentrations followed partly a biexponential and partly a monoexponential decline, the terminal elimination half-life (t0.5 beta or t0.5) being 1.4 +/- 0.3 hr.",Pharmacokinetics of clonazepam in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6732363/),h,1.4,59220,DB01068,Clonazepam
,6732363,bioavailability,"After oral administration absorption was rapid, but bioavailability poor and highly variable (20-60%).",Pharmacokinetics of clonazepam in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6732363/),%,20-60,59221,DB01068,Clonazepam
,6732363,Protein binding,Protein binding averaged 82% and is thus similar to man.,Pharmacokinetics of clonazepam in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6732363/),%,82,59222,DB01068,Clonazepam
,688725,turnover half-lives,Apparent enzyme(s) turnover half-lives ranged between 1 and 6 days.,Time-course of interaction between carbamazepine and clonazepam in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/688725/),d,1 and 6,70995,DB01068,Clonazepam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB01068,Clonazepam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB01068,Clonazepam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB01068,Clonazepam
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB01068,Clonazepam
,11704788,CL/F,"CL/F and the volume of distribution (V/F) were estimated to 9.23 l/h and 39.3 l, respectively, in a typical individual.",Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11704788/),[l] / [h],9.23,77230,DB01068,Clonazepam
,11704788,volume of distribution (V/F),"CL/F and the volume of distribution (V/F) were estimated to 9.23 l/h and 39.3 l, respectively, in a typical individual.",Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11704788/),l,39.3,77231,DB01068,Clonazepam
,30169515,absolute oral bioavailability (F),"The predicted absolute oral bioavailability (F) was 44% for midazolam (literature reported value, 31-72%) and 93% (literature reported value, ≥ 90%) for clonazepam.",In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169515/),%,44,89279,DB01068,Clonazepam
,30169515,absolute oral bioavailability (F),"The predicted absolute oral bioavailability (F) was 44% for midazolam (literature reported value, 31-72%) and 93% (literature reported value, ≥ 90%) for clonazepam.",In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169515/),%,93,89280,DB01068,Clonazepam
≥,30169515,absolute oral bioavailability (F),"The predicted absolute oral bioavailability (F) was 44% for midazolam (literature reported value, 31-72%) and 93% (literature reported value, ≥ 90%) for clonazepam.",In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169515/),%,90,89281,DB01068,Clonazepam
,483320,sensitivity,The sensitivity is 5 ng/ml of plasma for a valid quantitative determination.,[Direct determination of clonazepam (Rivotril) and 7-amino clonazepam in plasma by gas-chromatography (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/483320/),[ng] / [ml],5,94033,DB01068,Clonazepam
,3758147,plasma half-lives,"The plasma half-lives in these ""phenobarbital pretreated neonates' were of the same order of magnitude as those reported in adults (20-43 h).",Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758147/),h,20-43,97508,DB01068,Clonazepam
,11200924,Cmax,"The mean Cmax, Tmax t1/2 beta and AUC (0-48) for Epitril were: 16.31 +/- 3.07 ng/mL, 1.63 +/- 0.48 h, 46.97 +/- 12.26 h and 207.70 +/- 57.07 ng/ml.h; for reference brand were 19.75 +/- 5.95 ng/mL, 1.42 +/- 0.29 h, 46.88 +/- 11.29 h and 215.70 +/- 50.89 ng/ml.h respectively.",Comparative bioavailability study of clonazepam after oral administration of two tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11200924/),[ng] / [ml],16.31,98847,DB01068,Clonazepam
,11200924,Tmax t1/2 beta,"The mean Cmax, Tmax t1/2 beta and AUC (0-48) for Epitril were: 16.31 +/- 3.07 ng/mL, 1.63 +/- 0.48 h, 46.97 +/- 12.26 h and 207.70 +/- 57.07 ng/ml.h; for reference brand were 19.75 +/- 5.95 ng/mL, 1.42 +/- 0.29 h, 46.88 +/- 11.29 h and 215.70 +/- 50.89 ng/ml.h respectively.",Comparative bioavailability study of clonazepam after oral administration of two tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11200924/),h,1.63,98848,DB01068,Clonazepam
,11200924,Tmax t1/2 beta,"The mean Cmax, Tmax t1/2 beta and AUC (0-48) for Epitril were: 16.31 +/- 3.07 ng/mL, 1.63 +/- 0.48 h, 46.97 +/- 12.26 h and 207.70 +/- 57.07 ng/ml.h; for reference brand were 19.75 +/- 5.95 ng/mL, 1.42 +/- 0.29 h, 46.88 +/- 11.29 h and 215.70 +/- 50.89 ng/ml.h respectively.",Comparative bioavailability study of clonazepam after oral administration of two tablet formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11200924/),h,46.97,98849,DB01068,Clonazepam
,11200924,AUC (0-48),"The mean Cmax, Tmax t1/2 beta and AUC (0-48) for Epitril were: 16.31 +/- 3.07 ng/mL, 1.63 +/- 0.48 h, 46.97 +/- 12.26 h and 207.70 +/- 57.07 ng/ml.h; for reference brand were 19.75 +/- 5.95 ng/mL, 1.42 +/- 0.29 h, 46.88 +/- 11.29 h and 215.70 +/- 50.89 ng/ml.h respectively.",Comparative bioavailability study of clonazepam after oral administration of two tablet formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11200924/),[ng] / [h·ml],207.70,98850,DB01068,Clonazepam
,11200924,AUC (0-48),"The mean Cmax, Tmax t1/2 beta and AUC (0-48) for Epitril were: 16.31 +/- 3.07 ng/mL, 1.63 +/- 0.48 h, 46.97 +/- 12.26 h and 207.70 +/- 57.07 ng/ml.h; for reference brand were 19.75 +/- 5.95 ng/mL, 1.42 +/- 0.29 h, 46.88 +/- 11.29 h and 215.70 +/- 50.89 ng/ml.h respectively.",Comparative bioavailability study of clonazepam after oral administration of two tablet formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11200924/),[ng] / [h·ml],215.70,98851,DB01068,Clonazepam
,2057519,absolute systemic availability,"After oral dosage, absolute systemic availability (relative to intravenous administration) of both lorazepam and clonazepam was incomplete (mean values: 29 and 49%, respectively); however, metabolite levels were also correspondingly lower between oral and intravenous dosages.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),%,29,102045,DB01068,Clonazepam
,2057519,absolute systemic availability,"After oral dosage, absolute systemic availability (relative to intravenous administration) of both lorazepam and clonazepam was incomplete (mean values: 29 and 49%, respectively); however, metabolite levels were also correspondingly lower between oral and intravenous dosages.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),%,49,102046,DB01068,Clonazepam
,2057519,systemic/portal AUC ratios,"First-pass hepatic extraction also occurred for both drugs, with mean systemic/portal AUC ratios of 0.60 for lorazepam and 0.74 for clonazepam.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),,0.60,102047,DB01068,Clonazepam
,2057519,systemic/portal AUC ratios,"First-pass hepatic extraction also occurred for both drugs, with mean systemic/portal AUC ratios of 0.60 for lorazepam and 0.74 for clonazepam.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),,0.74,102048,DB01068,Clonazepam
,797496,half-life,It has a relatively long half-life (in adults 2 to 3 days; in children shorter).,Clinical pharmacokinetics of anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/797496/),d,2 to 3,104851,DB01068,Clonazepam
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB01068,Clonazepam
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB01068,Clonazepam
,14506315,ED(30),Vigabatrin inhibited the clonic pentetrazole-induced seizures and ED(30) of the drug was 879 mg/kg.,"Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],879,115573,DB01068,Clonazepam
,14506315,ED(30),"Vigabatrin (at the subthreshold dose of 250 mg/kg) potentiated the protective activity of ethosuximide, reducing its ED(30) from 142 to 95 mg/kg against clonic seizures induced by pentetrazole, but simultaneously elevated its plasma level.","Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],142,115574,DB01068,Clonazepam
,14506315,ED(30),"Vigabatrin (at the subthreshold dose of 250 mg/kg) potentiated the protective activity of ethosuximide, reducing its ED(30) from 142 to 95 mg/kg against clonic seizures induced by pentetrazole, but simultaneously elevated its plasma level.","Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],95,115575,DB01068,Clonazepam
,24021293,Plasma Tmax,"Plasma Tmax of clonazepam nanostructured carriers varied from 10-30 min., while their brain Tmax did not exceed 10 min, in comparison with 30 min for iv solution.","Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24021293/),min,10-30,119222,DB01068,Clonazepam
not exceed,24021293,Tmax,"Plasma Tmax of clonazepam nanostructured carriers varied from 10-30 min., while their brain Tmax did not exceed 10 min, in comparison with 30 min for iv solution.","Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24021293/),min,10,119223,DB01068,Clonazepam
,24021293,Tmax,"Plasma Tmax of clonazepam nanostructured carriers varied from 10-30 min., while their brain Tmax did not exceed 10 min, in comparison with 30 min for iv solution.","Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24021293/),min,30,119224,DB01068,Clonazepam
,24733513,flow rate,"After solid-phase extraction of 500 μL plasma, pinocembrin and the IS were separated on a Luna C8 column using the mobile phase composed of acetonitrile-0.3 mm ammonium acetate solution (65:35, v/v) at a flow rate of 0.25 mL/min in isocratic mode.",Determination of pinocembrin in human plasma by solid-phase extraction and LC/MS/MS: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733513/),[ml] / [min],0.25,119581,DB01068,Clonazepam
above,24733513,recovery,"The recovery was above 88% for the analyte at 1, 50 and 300 ng/mL.",Determination of pinocembrin in human plasma by solid-phase extraction and LC/MS/MS: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733513/),%,88,119582,DB01068,Clonazepam
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],127.7,122128,DB01068,Clonazepam
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],182.3,122129,DB01068,Clonazepam
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],198.3,122130,DB01068,Clonazepam
,19054418,time,The median time from hospital admission to ivLEV was 36 min.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),min,36,126739,DB01068,Clonazepam
,19054418,volume of distribution of central compartment,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [kg],0.45,126740,DB01068,Clonazepam
,19054418,total body clearance,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [h·kg],0.0476,126741,DB01068,Clonazepam
,19054418,"distribution rate constants, central to peripheral compartment (k(12))","Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.24,126742,DB01068,Clonazepam
,19054418,peripheral to central (k(21)),"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.70,126743,DB01068,Clonazepam
,19054418,maximal plasma concentration,Mean maximal plasma concentration was 85 (19) mg/L.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[mg] / [l],85,126744,DB01068,Clonazepam
,12640710,Vm,The children's phenytoin population pharmacokinetic parameters Vm and Km were 9.8 mg.,[Population pharmacokinetics of phenytoin in pediatric patients]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12640710/),mg,9.8,134513,DB01068,Clonazepam
,7639079,Vm,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),[mg] / [d],439,144566,DB01068,Clonazepam
,7639079,Km,"The Vm and Km of phenytoin in a 60 kg adult out-patient, without combination with other drugs (phenobarbital, clonazepam or diazepam) were estimated to be 439 mg.d-1 and 6.21 micrograms.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),μg,6.21,144567,DB01068,Clonazepam
,7639079,Vm,"The Vm of patients treated with phenytoin combined with phenobarbital, clonazepam or diazepam will increase 8.4 mg.",[NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639079/),mg,8.4,144568,DB01068,Clonazepam
,2400986,cerebrospinal fluid:plasma ratio,Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.,Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400986/),,1,151640,DB01068,Clonazepam
,20699074,Elimination half-life,"Elimination half-life is long, around 40 h.",[Therapeutic drug monitoring of clonazepam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20699074/),h,40,170848,DB01068,Clonazepam
,16239362,absorption half-life,"Based on nonlinear regression, mean kinetic variables for clonazepam were: absorption half-life, 24 minutes; elimination half-life, 40 hours; apparent oral clearance, 72 mL/min.",Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239362/),min,24,181931,DB01068,Clonazepam
,16239362,elimination half-life,"Based on nonlinear regression, mean kinetic variables for clonazepam were: absorption half-life, 24 minutes; elimination half-life, 40 hours; apparent oral clearance, 72 mL/min.",Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239362/),h,40,181932,DB01068,Clonazepam
,16239362,apparent oral clearance,"Based on nonlinear regression, mean kinetic variables for clonazepam were: absorption half-life, 24 minutes; elimination half-life, 40 hours; apparent oral clearance, 72 mL/min.",Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239362/),[ml] / [min],72,181933,DB01068,Clonazepam
,16239362,maximum average plasma clonazepam concentration,"The maximum average plasma clonazepam concentration was 3.0 ng/mL, reached at 72 hours after dosage.",Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239362/),[ng] / [ml],3.0,181934,DB01068,Clonazepam
,16239362,Overall systemic availability,"Overall systemic availability of clonazepam from the microsphere injection, relative to the conventional oral dosage form, was 1.05.",Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239362/),,1.05,181935,DB01068,Clonazepam
,12646763,maximum plasma concentration (C(max),"The absorption rates of clonazepam after i.m. and p.o. administration of clonazepam were significantly different from each other, as reflected by the respective mean values of maximum plasma concentration (C(max) 11.0 vs. 14.9 ng.ml(-1)) and time to reach maximum concentration (t(max) 3.1 vs. 1.7 h).","Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),[ng] / [ml],11.0,187514,DB01068,Clonazepam
,12646763,maximum plasma concentration (C(max),"The absorption rates of clonazepam after i.m. and p.o. administration of clonazepam were significantly different from each other, as reflected by the respective mean values of maximum plasma concentration (C(max) 11.0 vs. 14.9 ng.ml(-1)) and time to reach maximum concentration (t(max) 3.1 vs. 1.7 h).","Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),[ng] / [ml],14.9,187515,DB01068,Clonazepam
,12646763,time to reach maximum concentration (t(max),"The absorption rates of clonazepam after i.m. and p.o. administration of clonazepam were significantly different from each other, as reflected by the respective mean values of maximum plasma concentration (C(max) 11.0 vs. 14.9 ng.ml(-1)) and time to reach maximum concentration (t(max) 3.1 vs. 1.7 h).","Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),h,3.1,187516,DB01068,Clonazepam
,12646763,time to reach maximum concentration (t(max),"The absorption rates of clonazepam after i.m. and p.o. administration of clonazepam were significantly different from each other, as reflected by the respective mean values of maximum plasma concentration (C(max) 11.0 vs. 14.9 ng.ml(-1)) and time to reach maximum concentration (t(max) 3.1 vs. 1.7 h).","Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),h,1.7,187517,DB01068,Clonazepam
,12646763,C(max),Secondary plasma peaks of clonazepam were observed in 9 volunteers after i.m. injection (C(max) 9.9 ng.ml(-1); t(max) 10.4 h).,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),[ng] / [ml],9.9,187518,DB01068,Clonazepam
,12646763,t(max),Secondary plasma peaks of clonazepam were observed in 9 volunteers after i.m. injection (C(max) 9.9 ng.ml(-1); t(max) 10.4 h).,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),h,10.4,187519,DB01068,Clonazepam
,12646763,AUC(0- infinity ),A comparison of the area under the plasma concentration-time curves (AUC) shows that the i.m. route is equivalent to the oral route (AUC(0- infinity ) 620 vs. 561 ng.h.ml(-1)).,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),[h·ng] / [ml],620,187520,DB01068,Clonazepam
,12646763,AUC(0- infinity ),A comparison of the area under the plasma concentration-time curves (AUC) shows that the i.m. route is equivalent to the oral route (AUC(0- infinity ) 620 vs. 561 ng.h.ml(-1)).,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),[h·ng] / [ml],561,187521,DB01068,Clonazepam
,12646763,absolute bioavailability,"Clonazepam was almost completely absorbed after i.m. and p.o. administration, as shown by the mean absolute bioavailability of 93 and 90%, respectively.","Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),%,93,187522,DB01068,Clonazepam
,12646763,absolute bioavailability,"Clonazepam was almost completely absorbed after i.m. and p.o. administration, as shown by the mean absolute bioavailability of 93 and 90%, respectively.","Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),%,90,187523,DB01068,Clonazepam
,12646763,elimination half-lives,No significant differences existed between the elimination half-lives (i.v. 38.0 h; i.m. 43.6 h; p.o. 39.0 h).,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),h,38.0,187524,DB01068,Clonazepam
,12646763,elimination half-lives,No significant differences existed between the elimination half-lives (i.v. 38.0 h; i.m. 43.6 h; p.o. 39.0 h).,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),h,43.6,187525,DB01068,Clonazepam
,12646763,elimination half-lives,No significant differences existed between the elimination half-lives (i.v. 38.0 h; i.m. 43.6 h; p.o. 39.0 h).,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),h,39.0,187526,DB01068,Clonazepam
,12646763,clearance,The average clearance and volume of distribution (V(Z)) were 55 ml.,"Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12646763/),ml,55,187527,DB01068,Clonazepam
,1687613,terminal elimination half-life,"Alprazolam has an average terminal elimination half-life of 12 hours, whereas adinazolam generates a metabolite responsible for its benzodiazepine effects whose half-life is less than 3 hours.","Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687613/),h,12,190476,DB01068,Clonazepam
less,1687613,half-life,"Alprazolam has an average terminal elimination half-life of 12 hours, whereas adinazolam generates a metabolite responsible for its benzodiazepine effects whose half-life is less than 3 hours.","Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687613/),h,3,190477,DB01068,Clonazepam
,1687613,half-life,Clonazepam shows a much slower elimination with a half-life of 20 to 80 hours.,"Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687613/),h,20 to 80,190478,DB01068,Clonazepam
,110917,biological half-life,The biological half-life of the 7-amino metabolite (2.2 +/- 1.0 hr) was shorter than that of clonazepam (4.9 +/- 0.2 hr).,Kinetics of biotransformation of clonazepam to its 7-amino metabolite in the monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/110917/),h,2.2,194929,DB01068,Clonazepam
,110917,biological half-life,The biological half-life of the 7-amino metabolite (2.2 +/- 1.0 hr) was shorter than that of clonazepam (4.9 +/- 0.2 hr).,Kinetics of biotransformation of clonazepam to its 7-amino metabolite in the monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/110917/),h,4.9,194930,DB01068,Clonazepam
,110917,Total body clearance,Total body clearance of the metabolite (0.83 +/- 0.16 liters/hr/kg) was larger than that of the parent drug (0.55 +/- 0.09 liters/hr/kg).,Kinetics of biotransformation of clonazepam to its 7-amino metabolite in the monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/110917/),[l] / [h·kg],0.83,194931,DB01068,Clonazepam
,110917,Total body clearance,Total body clearance of the metabolite (0.83 +/- 0.16 liters/hr/kg) was larger than that of the parent drug (0.55 +/- 0.09 liters/hr/kg).,Kinetics of biotransformation of clonazepam to its 7-amino metabolite in the monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/110917/),[l] / [h·kg],0.55,194932,DB01068,Clonazepam
,110917,fraction,The fraction of a dose of clonazepam appearing in the systemic circulation as 7-amino metabolite was 0.70 +/- 0.30.,Kinetics of biotransformation of clonazepam to its 7-amino metabolite in the monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/110917/),,0,194933,DB01068,Clonazepam
,7640154,Cmax,A Cmax of 6.3 +/- 1.0 ng ml-1 (mean; +/- s.d.) was measured 17.5 min (median) (range 15-20 min) after intranasal administration.,Absorption of clonazepam after intranasal and buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640154/),[ng] / [ml],6.3,196321,DB01068,Clonazepam
,7640154,peak,A second peak (4.6 +/- 1.3 ng ml-1) caused by oral absorption was seen after 1.7 h (range 0.7-3.0 h).,Absorption of clonazepam after intranasal and buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640154/),[ng] / [ml],4.6,196322,DB01068,Clonazepam
,7640154,Cmax,After buccal administration a Cmax of 6.0 +/- 3.0 ng ml-1 was measured after 50 min (range 30-90 min) with a second peak of 6.5 +/- 2.5 ng ml-1 after 3.0 h (range 2.0-4.0 h).,Absorption of clonazepam after intranasal and buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640154/),[ng] / [ml],6.0,196323,DB01068,Clonazepam
,7640154,second peak,After buccal administration a Cmax of 6.0 +/- 3.0 ng ml-1 was measured after 50 min (range 30-90 min) with a second peak of 6.5 +/- 2.5 ng ml-1 after 3.0 h (range 2.0-4.0 h).,Absorption of clonazepam after intranasal and buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640154/),[ng] / [ml],6.5,196324,DB01068,Clonazepam
,7640154,serum concentration,Two minutes after i.v. injection of 0.5 mg clonazepam the serum concentration was 27 +/- 18 ng ml-1.,Absorption of clonazepam after intranasal and buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640154/),[ng] / [ml],27,196325,DB01068,Clonazepam
,621234,sensitivity limit,The sensitivity limit of the method is about 1 ng/ml plasma for both drugs.,Assay of underivatized intrazepam and clonazepam in plasma by capillary gas chromatography applied to pharmacokinetic and bioavailability studies in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/621234/),[ng] / [ml],1,210779,DB01068,Clonazepam
,621234,elimination half-life,The mean elimination half-life of nitrazepam was 27 h (range 13-34 h).,Assay of underivatized intrazepam and clonazepam in plasma by capillary gas chromatography applied to pharmacokinetic and bioavailability studies in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/621234/),h,27,210780,DB01068,Clonazepam
,18720141,minimal effective concentration,"With a droplet of propylene glycol loaded with 2.5% (wt/wt) CZ and 5.0% (wt/wt) OA, the plasma concentration reached 20 ng/mL (minimal effective concentration) within 10 min and was maintained between 20 and 60 ng/mL, less than a toxic level, for a period of 60 min.",Clonazepam oral droplets for the treatment of acute epileptic seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18720141/),[ng] / [ml],20,217739,DB01068,Clonazepam
,2743491,bioavailability,"When the Hipore 4050 system with an increased amount of ointment and enlarged absorption area (0.5 g, 4.0 cm2) was applied, the therapeutic range was sustained for about 40 h, and slightly higher plasma levels over the whole application period and much higher bioavailability (37%) were obtained compared with those after the 2.25 cm2-Hipore 4050 system.",Membrane-controlled transdermal therapeutic system containing clonazepam and anticonvulsant activity after its application. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743491/),%,37,227243,DB01068,Clonazepam
,12142639,peak concentration (Cmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),[ng] / [ml],20.9,246667,DB01068,Clonazepam
,12142639,time intervals from dosing to Cmax (Tmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),[ng] / [ml],113.8,246668,DB01068,Clonazepam
,12142639,time intervals from dosing to Cmax (Tmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),h,1,246669,DB01068,Clonazepam
,12142639,time intervals from dosing to Cmax (Tmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),h,1.5,246670,DB01068,Clonazepam
,23584079,m/,The mass transition ion-pair was followed as m/z 471.3→281.2 for WA; m/z 437.2→292.2 for tianeptine (IS) and m/z 488.3→263.1 for WLD; m/z 315.9→270 for clonazepam (IS).,Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584079/),,437.2,247953,DB01068,Clonazepam
,23584079,m/z,The mass transition ion-pair was followed as m/z 471.3→281.2 for WA; m/z 437.2→292.2 for tianeptine (IS) and m/z 488.3→263.1 for WLD; m/z 315.9→270 for clonazepam (IS).,Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584079/),,315.9,247954,DB01068,Clonazepam
,23584079,m/z,The mass transition ion-pair was followed as m/z 471.3→281.2 for WA; m/z 437.2→292.2 for tianeptine (IS) and m/z 488.3→263.1 for WLD; m/z 315.9→270 for clonazepam (IS).,Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584079/),,270,247955,DB01068,Clonazepam
less,10794928,T(max)'s,Both DZ and CZ were absorbed very rapidly from 1% SGC/60% PG-30% EtOH-10% Water after IN single application; the T(max)'s were less than 2 min.,Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),min,2,255791,DB01068,Clonazepam
,10794928,peak time,The absorption rate of MCA was relatively slower with the peak time of 13-32 min.,Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),min,13-32,255792,DB01068,Clonazepam
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,77,255793,DB01068,Clonazepam
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,45,255794,DB01068,Clonazepam
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,79,255795,DB01068,Clonazepam
,21247373,effective concentration,The effective concentration for humans and rats (20 ng/mL or more) was achieved within 30 min after buccal administration for both PEG/CZ/OA and PEG/CZ.,Semi-solid dosage form of clonazepam for rapid oral mucosal absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21247373/),[ng] / [ml],20,257888,DB01068,Clonazepam
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,24.2,260824,DB01068,Clonazepam
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,10.3,260825,DB01068,Clonazepam
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,75.2,260826,DB01068,Clonazepam
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,66.6,260827,DB01068,Clonazepam
,1424422,half-life,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),h,20,267843,DB01068,Clonazepam
,1424422,half-life,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),h,17,267844,DB01068,Clonazepam
,1424422,clearance,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),[ml] / [min],48,267845,DB01068,Clonazepam
,1424422,clearance,"When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min).",Fluoxetine impairs clearance of alprazolam but not of clonazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424422/),[ml] / [min],61,267846,DB01068,Clonazepam
,10653204,apparent oral clearance,"Clonazepam apparent oral clearance, volume of distribution, and half-life were 3.9 +/- 0.2 L/hr, 233 +/-11 L, and 40.5 +/- 0.3 hours, respectively.",Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653204/),[l] / [h],3.9,269773,DB01068,Clonazepam
,10653204,volume of distribution,"Clonazepam apparent oral clearance, volume of distribution, and half-life were 3.9 +/- 0.2 L/hr, 233 +/-11 L, and 40.5 +/- 0.3 hours, respectively.",Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653204/),l,233,269774,DB01068,Clonazepam
,10653204,half-life,"Clonazepam apparent oral clearance, volume of distribution, and half-life were 3.9 +/- 0.2 L/hr, 233 +/-11 L, and 40.5 +/- 0.3 hours, respectively.",Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653204/),h,40.5,269775,DB01068,Clonazepam
